Cancer Clinical Trials

BREAST

A011801: The COMPASSHER2 Trials ( COMprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatnib.

Alliance

D/N/VBMC

NCICIRB

A191901:Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions

Alliance

D/N/VBMC

NCICIRB

A012103: OptimICE-pCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy

Alliance

D/N/VBMC

NCICIRB

CCTG MA.39: Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer

CCTG

N

NCICIRB

ASCENT-05/OptimICE-RD: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy.

Gilead

D/N/VBMC

Advarra

C4391022: An Interventional, Open-Label, Randomized, Multicenter Phase 3 Study Of Pf-07220060 Plus Fulvestrant Compared To Investigator’s Choice Of Therapy In Participants Over 18 Years Of Age With Hormone Receptor-Positive, Her2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK 4/6 Inhibitor Based Therapy

Pfizer

D/N/VBMC

Advarra

LUNG

A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial

Alliance

D/VBMC

CIRB/VIRB

E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

ECOG-ACRIN

D/ VBMC

CIRB

S2302:PRAGMATICA: A prospective randomized study Ramucirumab plus Pembrolizumab VS standard of care for participants previously treated with immunotherapy for stage IV or recurrent NSCLC

SWOG

D/N

CIRB

PRESERVE-003: Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors

OncoC4

D/N/VBMC

WIRB

Skin

S2015: Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Radomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma

SWOG

VBMC

CIRB

GYN

NRG-CC008: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]

NRG

D/N

CIRB

NRG-GY026: A Phase II/III Study of Paclitaxel/Carboplatin alone or combined with Either Trastuzumab and Hyaluronidase-OYSK (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-ZZXF (PHESGO) in HER2 positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

NRG

D/N

CIRB

PRESERVE-004/GOG-3081: Phase 2 Randomized Open label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Trearment of Patients with Platinum Resistant Ovarian Cancer(PROC)

GOG

D/N

CIRB

GU

NRG-GU010: Parallel Phase III Randomized Trials of Genomic Risk Stratified Unfavourable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation(GUIDANCE)

NRG

N

CIRB

Pancreas

15-10: The Role of MicroRNAs in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer

Frank

N/D/VBMC

BRANY

16-15: Pre- and Post-Surgical Molecular Testing in Individuals with Operable Pancreatic Cancer

Frank, Seshadri Martignetti

N/D/VBMC

BRANY

16-17: A Pancreatic Cancer Screening Study in High Risk Individuals

Frank

N/D/NM

BRANY

18-01: A Pancreatic Cancer Screening Study in High Risk Individuals Including those with Recent-Onset Diabetes Mellitus

Frank

N/D/NM

BRANY

A021806: A phase III trial of perioperative versus adjuvant chemotherapy for resectable pancreatic cancer

Alliance/NRG

D/N

CIRB

S2001: Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations

SWOG/NRG

D/N

CIRB

Translational

2200003 (PACT): A Prospective Study to Achieve Health Equity in Biomarker Analysis for Underrepresented Communities Receiving Cancer Treatment at Nuvance Health

Versea

D/N/VBMC

BRANY

Observational Immunotherapy

S2013: Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

NRG

D/N/VBMC

CIRB

Heme

MonumenTAL-3: A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumuab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Thearpy

Janssen

N

Sterling

Basket Trial

C2321001: A Phase I dose escalation and expanded cohort study of PF-06821497 in the treatment of adult patients with Relapsed/refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and follicular lymphoma

Pfizer

N

WIRB

AMG 510 20190135: A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

Amgen

N

WIRB

ONC-392-001: Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study.

OncoC4

N/D

WIRB

Novita:NP-G2-044-P2-01: NP-G2-044-P2-01 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

Novita

N/D

WIRB